Shielded by tariffs and fostered by subsidies, a solar panel commands triple the price in the U.S. compared with China and Europe, but expanding in America has become trickier. Oil prices end at ...

During the past decade or so, technological advancements in the sequencing industry have largely been led by Illumina and brought down the cost of assembling one genome from nearly $3 billion in the ...

As of Oct. 31, the price/fair value metric of the US stock market was 1.02, representing a 2% premium to our fair value ...

While Palantir has only posted GAAP profitability in one year (2023), we expect the firm to continue this trend while generating strong cash flow margins as it increases its operating leverage by ...

SYDNEY--The Reserve Bank of Australia left official interest rates on hold, chalking up a full year without fundamentally changing its policy stance while also not ruling out a further interest rate ...

Chinese shares rallied after a private gauge of China's services sector showed a strong October reading, adding to recent signs that Beijing's stimulus push is revitalizing the world's second-largest ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

"China remains confident on reaching this year's GDP growth target and future economic outlook," Premier Li Qiang said at the opening ceremony of the China International Import Expo Tuesday. The ...

Domino's Pizza Enterprises is the Australian master licence holder of the Domino's Pizza brand. It also has operations in New Zealand, Japan, Singapore, Malaysia, France, Germany, Belgium, Luxembourg, ...

Palantir Technologies Inc. posted accelerating quarterly growth on Monday afternoon, again fueled by artificial intelligence.

Marqeta cut its losses roughly in half, posting a net loss of $28.64 million, or 6 cents a share, while analysts tracked by FactSet were forecasting a 5-cent loss per share. The company generated ...

The results come as those drugs, like Wegovy and Ozempic, explode in popularity, leading to shortages as well as greater competition. Executives on Monday said those supply constraints were "not ...